

Olivier S Descamps

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2139381/publications.pdf>

Version: 2024-02-01

27
papers

8,407
citations

394421

19
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

8715
citing authors

#	ARTICLE	IF	CITATIONS
1	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
2	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
3	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
4	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
5	Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. <i>Lancet, The</i> , 2013, 381, 1293-1301.	13.7	485
6	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
7	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	2.8	216
8	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
9	Plant sterols and cardiovascular disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2012, 33, 444-451.	2.2	180
10	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
11	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. <i>Atherosclerosis</i> , 2014, 233, 83-90.	0.8	52
12	Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. <i>Atherosclerosis</i> , 2011, 217, 308-321.	0.8	43
13	Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <i>Atherosclerosis</i> , 2020, 292, 178-187.	0.8	41
14	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	3.1	39
15	Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. <i>Atherosclerosis</i> , 2004, 172, 287-298.	0.8	36
16	Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1412-1443.	2.4	36
17	Lipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children. <i>Journal of Lipid Research</i> , 2005, 46, 2405-2414.	4.2	34
18	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31

#	ARTICLE	IF	CITATIONS
19	Variability of the LDL-C lowering response to ezetimibe and ezetimibe+statin therapy in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2015, 240, 482-489.	0.8	29
20	Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <i>Atherosclerosis</i> , 2021, 319, 108-117.	0.8	18
21	Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. <i>International Journal of Clinical Practice</i> , 2017, 71, e12979.	1.7	11
22	A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. <i>Atherosclerosis</i> , 2012, 222, 564-566.	0.8	9
23	A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of 50 577	0.784314	10
24	Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II _{CHD}). <i>Acta Clinica Belgica</i> , 2019, 74, 399-404.	1.2	4
25	Does FTO have a paradoxical effect in fetal life?. <i>BMC Genetics</i> , 2014, 15, 145.	2.7	3
26	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	1.2	3
27	Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy. <i>Acta Cardiologica</i> , 2021, 76, 227-235.	0.9	3